In patients with stage II-III HER2+ breast cancer who were not treated with neoadjuvant therapy, without having knowledge of response to neoadjuvant therapy (i.e. pCR or not) after chemotherapy, what is your preferred adjuvant HER2 directed therapy?
Which patients should receive TDM-1, Trastuzumab+Pertuzumab or Trastuzumab alone?